Clinical Trials Browser

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05411094 2026-03-18

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

55 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Phase 1 Recruiting

40 enrolled

Gynecologic

Neoplasms, Ovarian Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1 Recruiting

18 enrolled

BRCA1 Mutation

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

50 enrolled

Gynecologic

Fallopian Tube Neoplasms

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

220 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05900895 2025-11-20

PHOEBE

Phase 1 Recruiting

6 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06130254 2025-10-14

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Recruiting

52 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

429 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06488378 2025-08-22

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Phase 1 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Phase 1 Recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT05870423 2025-06-05

PRRT-PARPi

Phase 1 Recruiting

24 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06686745 2025-01-07

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Recruiting

130 enrolled

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Study of INCB123667 in Subjects With Advanced Solid Tumors

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

CONCORDE

PHOEBE

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

PRRT-PARPi

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors